facebook button Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Advanced or Metastatic Solid Tumors Exelixis: Cabozantinib plus Atezolizumab for Subjects with Locally Advanced or Metastatic Solid Tumors Exelixis
Solid Tumors STARTRK-2 Ignyta, Inc.
Solid Tumor or Lymphoma Zai Lab: ZL-1201-001 Zai Lab (Shanghai) Co., Ltd.
Chemotherapy-Induced Oral Mucositis Chemo Mouthpiece Medical Device Trial Chemo Mouthpiece, LLC
Ovarian Cancer EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib Ellipses Pharma
Small Cell Lung Cancer Ipsen RESILIENT: Second Line Irinotecan Versus Topotecan IPSEN Bioscience, Inc.
Metastatic Non-small Cell Lung, or Extensive Stage Small-cell Lung GX41563: Genentech, Inc.: Prospective Clinicogenomic Program (PCG) Genentech, Inc.
Non-Small Cell Lung Cancer Spectum: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Non-Small Cell Lung Cancer LEAP-008: Second Line Lenvatinib and Pembrolizumab Merck Sharp & Dohme Corp.
Non-Small Cell Lung Cancer TROPION-Lung05: DS-1062a in NSCLC with actionable genetic mutations Daiichi Sankyo, Inc.
Solid Tumors MyTACTIC: Multiple Cohort Solid Tumor Trial Genentech, Inc.
Solid Tumors BO TAPISTRY: Multiple Cohort Solid Tumor Trial Hoffmann-La Roche
Breast Cancer DS8201a in HER2+ Patients Previously Treated with T-DM1 Daiichi Sankyo, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
Diffuse Large B-Cell Lymphoma Seagen: Brentuximab Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Seagen
Oropharynx or Oral Cavity Cancer Galera ROMAN: GC4419 for Radiation Induced Oral Mucositis Galera Therapeutics, Inc.
Prostate Cancer GO27983: Ipatasertib for Patients Previously Treated with Androgen Deprivation Therapy Genentech, Inc.
Triple Negative Breast Cancer CONTESSA Trio: Tesetaxel Plus Immunotherapy Odonate Therapeutics, Inc.
Metastatic Castration-Resistant Prostate Cancer CA209-7DX: Bristol-Myers Squibb Bristol-Myers Squibb
Non-Small Cell Lung Cancer Zeno: ZN-e4-001 Zeno Pharmaceuticals, Inc.
Chemotherapy Induced Anemia Fibrogen: Roxadustat for Patients with Chemotherapy Induced Anemia FibroGen, Inc.
Pancreatic Cancer Ipsen Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel Ipsen
Hematologic Malignancies KPG-818 for Patients with Hematologic Malignancies Kangpu Biopharmaceuticals, Ltd.
Solid Tumors Clovis LODESTAR: Rucaparib in HRD Mutated Solid Tumors Clovis Oncology, Inc.
Solid Tumors Merck KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors Merck Sharp & Dohme Corp.
Urothelial Carcinoma Basilea: Derzantinib for Patients with a Mutation in FGFR1-3 Basilea Pharmaceutica
Non-small Cell Lung Cancer D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer AstraZeneca
Non-Small Cell Lung Cancer CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation Amgen Inc.
Cutaneous Squamous Cell Carcinoma Regeneron CASE: CemiplimAb in Cutaneous Squamous Cell Carcinoma Regeneron Pharmaceuticals, Inc.